Evidence map›Paper›PMID 32580641›Full record

ArticleJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners2020

Practical strategies to manage cancer patients during the COVID-19 pandemic: Saudi Oncology Pharmacy Assembly Experts recommendations.

Majed Alshamrani, Atika AlHarbi, Nora Alkhudair, Fouad AlNajjar, Mansoor Khan, Abdulaziz Ben Obaid, Amr Khardaly, Eshtyag Bajnaid, Hadeel Samarkandi, Aeshah AlAzmi and 2 more

Abstract read
In one paragraph

Article in Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Experiences of patients and providers while using telemedicine in cancer care during COVID-19 pandemic: a systematic review and meta-synthesis of qualitative literature.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Majed AlshamraniSaudi Oncology Pharmacy Assembly, Riyadh, Saudi Arabia.ORCID https://orcid.org/0000-0001-8747-7271
Atika AlHarbiPharmaceutical Care Services, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia.ORCID https://orcid.org/0000-0003-1057-7631
Nora AlkhudairSaudi Oncology Pharmacy Assembly, Riyadh, Saudi Arabia.ORCID https://orcid.org/0000-0002-5998-4345
Fouad AlNajjarSaudi Oncology Pharmacy Assembly, Riyadh, Saudi Arabia.
Mansoor KhanPharmaceutical Care Services, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia.ORCID https://orcid.org/0000-0002-3702-3754
Abdulaziz Ben ObaidSaudi Oncology Pharmacy Assembly, Riyadh, Saudi Arabia.
Amr KhardalySaudi Oncology Pharmacy Assembly, Riyadh, Saudi Arabia.
Eshtyag BajnaidClinical Pharmacy Department, King Abdullah Medical City, Mecca, Saudi Arabia.
Hadeel SamarkandiDepartment of Pharmaceutical Care, Oncology Pharmacy Services, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia.
Aeshah AlAzmiPharmaceutical Care Services, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia.ORCID https://orcid.org/0000-0002-2761-7559
Salman AlabdaliKing Fahad Hospital, Ministry of Health, Almadina, Saudi Arabia.
Mohammed AlNahedhSaudi Oncology Pharmacy Assembly, Riyadh, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeDuring COVID-19 pandemic, cancer patients are considered one of the most vulnerable to infection since they tend to have advanced age, multiple comorbidities, and are often immunosuppressed by their cancer or therapy. Hence, the Saudi Oncology Pharmacy Assembly has issued recommendations to reduce the frequency of cancer patients' visits to oncology centers during the pandemic while maintaining the access to cancer therapy and minimize the risk of exposure to coronavirus disease. MATERIALS AND

methodsA qualitative methodological approach was conducted in April 2020 using a virtual panel discussion for collection of recommendations.

resultsA total of 12 expert oncology pharmacy practitioners shared their knowledge and experiences in managing oncology patients during the COVID-19 pandemic. The participants recognized many fundamental recommendations that were already applied in many cancer centers since the start of the COVID-19 outbreak. On that basis, the panelists developed eight practice-related recommendations for action, with a main focus on cancer treatment modification.

conclusionsIn conclusion, delivering cancer care during the COVID-19 pandemic carries significant challenges. This paper addressed suggestions to properly manage cancer patients during difficult times. Implementing changes in practice mandates a national collaborative effort from different sectors to guarantee the quality and continuity of care. The SOPA expert panel developed these recommendations, to ultimately contribute in maintaining access to cancer therapy while minimizing the risk of COVID-19 exposure.

Indexed as

Coronavirus InfectionsCOVID-19HumansMedical OncologyNeoplasmsPandemicsPharmaceutical ServicesPneumonia, ViralSaudi ArabiacancerCoronavirusCOVID-19pandemicSOPA

Identifiers

PMID32580641
PMCPMC7448793

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.